Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition. On February 27, 2026, he had 36,523 shares of common stock disposed of at $232.08 per share to satisfy tax obligations. After this tax-withholding disposition, he directly owned 178,737 shares of AbbVie common stock.
AbbVie Inc. executive vice president and chief commercial officer Jeffrey Ryan Stewart reported a tax-withholding disposition of 23,812 shares of common stock at $232.08 per share on February 27, 2026. After this transaction, he directly owned 83,171 shares. An additional 1,338 shares are held indirectly by his spouse in a trust, and he disclaims beneficial ownership of those securities.
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions. On February 27, 2026, he disposed of 14,850 common shares at $232.08 per share to cover tax obligations. On March 2, 2026, he conducted open-market sales totaling 18,668 common shares at weighted average prices between about $233 and $235.36. Following these sales, his directly owned common stock holdings were reported in the filing at reduced levels after each transaction.
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported a tax-related share disposition under a compensation plan. On February 27, 2026, 21,638 shares of AbbVie common stock were disposed of to cover tax withholding obligations. After this transaction, he directly owned 38,777 AbbVie shares.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition. On February 27, 2026, he transferred 2,692 shares of AbbVie common stock at $232.08 per share to cover tax obligations, described as a payment of tax liability by delivering securities.
After this transaction, he directly owned 7,884 shares of AbbVie common stock. He also had an indirect holding of 543 shares through a profit sharing trust, with a footnote noting this balance in an AbbVie savings program as of February 20, 2026, including shares acquired via a dividend reinvestment feature.
AbbVie Inc. executive Azita Saleki‑Gerhardt reported a tax-related share disposition. On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at $232.08 per share to satisfy tax obligations through share withholding, a non‑open‑market transaction. Following this, she directly held 197,794 AbbVie shares.
In addition, 2,706 AbbVie shares were held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings Program as of February 20, 2026, including dividend reinvestments. A further 3,873 shares were held by her spouse, for which the reporting person disclaims beneficial ownership.
AbbVie Inc. executive Nicholas Donoghoe reported a tax-related share disposition under a compensation plan. On February 27, 2026, he used 12,874 shares of common stock, valued at $232.08 per share, to cover tax withholding. After this transaction, he directly held 74,430 shares of AbbVie common stock.
ABBV insider sale notice: A Form 144 filing lists performance shares to be sold by an issuer-related plan, showing 18,668 units tied to 02/28/2026. The filing also records a prior sale by Perry C. Siatis of 22,381 shares on 02/25/2026 for $5,147,630.00.
AbbVie Inc. executive Perry C. Siatis, EVP, General Counsel and Secretary, reported multiple stock option exercises and a related share sale. On February 25, 2026, he exercised options covering 7,314, 7,775 and 7,292 AbbVie shares at exercise prices of $149.62, $175.28 and $192.86 per share under the AbbVie Amended and Restated 2013 Incentive Stock Program. These exercises delivered an equal number of AbbVie common shares. On the same date, he sold 22,381 AbbVie shares in an open-market transaction at $230.00 per share. After these transactions, Siatis directly held 38,137 AbbVie common shares.
AbbVie Inc. entered into an underwriting agreement to issue and sell multiple series of senior notes with expected net proceeds of approximately $7.95 billion. The transaction includes floating rate notes due 2028 and fixed-rate notes maturing between 2028 and 2066.
AbbVie plans to use the proceeds to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026, of which $2.0 billion is currently outstanding, and for general corporate purposes, which may include repayment or repurchase of other outstanding debt.